Understand the source comparison
Adult-Onset vs Childhood-Onset GH Deficiency: Why Response Rates Differ
Peptides help with growth hormone deficiency most effectively in adult-onset cases where the pituitary remains structurally intact but functionally suppressed. Age-related GH decline. Beginning around age 30 and accelerating after 50. Stems primarily from redu
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Peptides help with growth hormone deficiency most effectively in adult-onset cases where the pituitary remains structurally intact but functionally suppressed. Age-related GH decline. Beginning around age 30 and accelerating after 50. Stems primarily from reduced hypothalamic GHRH output and increased somatostatin tone, not from somatotroph cell loss. When you stimulate a dormant but viable pituitary with exogenous GHRH analogs or ghrelin mimetics, the gland responds. A 2021 study in Endocrine Reviews found that adults over 60 with low IGF-1 (<150 ng/mL) showed GH secretory responses to GHRP stimulation that were 60-75% of young adult baseline. Diminished but far from absent.
- Childhood-onset GH deficiency presents a different challenge. When deficiency results from congenital hypopituitarism, pituitary tumor damage, or cranial radiation, the somatotroph cell population may be permanently reduced or non-functional. Peptides can't regenerate destroyed tissue or stimulate cells that don't exist. In these cases, exogenous rhGH remains the standard because no amount of receptor activation compensates for structural absence. The diagnostic distinction matters: patients with isolated GH deficiency (normal prolactin, TSH, ACTH, LH/FSH) often retain enough somatotrophs to respond to peptide therapy, while those with panhypopituitarism typically do not.
- Here's the honest answer: peptides work exceptionally well for age-related GH decline and hypothalamic insufficiency. Conditions where the pituitary is intact but understimulated. They don't work for structural pituitary damage. If serum GH remains undetectable after GHRP stimulation testing, peptides won't restore function. This is why baseline stimulation testing (arginine-GHRP test, insulin tolerance test) is essential before committing to long-term peptide protocols. Our team has reviewed this across hundreds of research cases: response rates in adult-onset deficiency exceed 80%, but in childhood-onset structural deficiency, they fall below 20%.